- In July 2026, NeoGenomics, Inc. launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma, enabling identification of PTEN-deficient tumors in patients who may be eligible for AstraZeneca’s TRUQAP (capivasertib), with testing available across its national oncology laboratory network.
- This test not only extends NeoGenomics’ presence into urologic oncology but also deepens its role in personalized prostate cancer care through rapid, integrated molecular workups such as NEO PanTracer Pro.
- We’ll now explore how this first-of-its-kind PTEN IHC companion diagnostic could reshape NeoGenomics’ investment narrative and growth opportunities.
Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
NeoGenomics Investment Narrative Recap
To own NeoGenomics, you need to believe its expanding oncology test menu can eventually scale into a more profitable, less volatile business. The PTEN IHC CDx launch reinforces the personalized medicine catalyst in the near term, but it does not remove the key risks around competition, reimbursement, and the company’s history of losses, which still matter more than any single test win.
Among recent developments, Medicare MolDX coverage for PanTracer LBx stands out as especially relevant. Together with PTEN IHC CDx and NEO PanTracer Pro, it underscores NeoGenomics’ push to build an integrated tissue and liquid biopsy offering across solid tumors, which could strengthen its NGS positioning but also raises the stakes if new product adoption or pricing falls short of expectations.
Yet while the PTEN IHC CDx launch looks promising, investors should also be aware of the ongoing pressure from intensifying competition and...
Read the full narrative on NeoGenomics (it's free!)
NeoGenomics' narrative projects $982.4 million revenue and $59.9 million earnings by 2029. This requires 9.6% yearly revenue growth and a $159.1 million earnings increase from -$99.2 million today.
Uncover how NeoGenomics' forecasts yield a $15.06 fair value, a 7% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming revenue could reach about US$1.0 billion and positive earnings by 2029, so this FDA-approved PTEN IHC CDx win may eventually support their view that new companion diagnostics can offset pharma weakness, but it could just as easily prompt you to question how realistic those growth and margin assumptions really are.
Explore 2 other fair value estimates on NeoGenomics - why the stock might be worth just $15.06!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your NeoGenomics research is our analysis highlighting 1 important warning sign that could impact your investment decision.
- Our free NeoGenomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NeoGenomics' overall financial health at a glance.
Curious About Other Options?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com